Business
Achieve Life Sciences Announces Presentation of Additional Cytisinicline Analyses at the Society for Research on Nicotine & Tobacco (SRNT) Annual Meeting
SEATTLE and VANCOUVER, British Columbia, March 12, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company
About this update from Achieve Life Sciences, Inc.
[{"type":"text","content":"SEATTLE and VANCOUVER, British Columbia, March 12, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced that additional analyses from the ORCA-1 Phase 2b trial will be presented today, Thursday, March 12th, at the SRNT Annual Meeting in New Orleans. \n\n \n \n \n \n \n \n\n \nPreviously reported data from the ORCA-1 trial of 254 smokers demonstrated significant quit rates in all cytisinicline-treated subjects compared to placebo, particularly in the 3.0 mg cytisinicline-treated three times daily (TID) arm. Smokers who received 3.0 mg cytisinicline dosed TID over 25 days demonstrated a 54% abstinence rate at week 4 compared to 16% for placebo (p \nNew analyses from the ORCA-1 trial indicate that the cytisinicline benefit, abstinence and reduction in number of cigarettes smoked, was consistently observed across all demographics, smoking history, and clinical trial locations. Additionally, clinical benefit was observed with cytisinicline regardless of prior smoking cessation treatments utilized, including Chantix® (varenicline), Zyban® (bupropion), or Nicotine Replacement Therapy (NRT). Smokers in the ORCA-1 trial had an average smoking history of 32.1 years, smoked 18 cigarettes per day, and had 4.5 previous quit attempts, indicating a highly nicotine-addicted population. \nNew analyses also demonstrate cytisinicline biochemical efficacy via measurement of serum cotinine as well as the previously reported carbon monoxide (CO) efficacy. Similar to CO analyses, all subjects in the cytisinicline-treated arms had a statistically significant reduction in serum cotinine levels by the end of study treatment. Both expired CO and serum cotinine levels are biochemical products from cigarette smoking or metabolizing nicotine and were objective biochemical markers used in the study to assess cigarette smoking or nicotine intake.\n\"The additional analyses further validate our belief that cytisinicline could be an effective aid to smoking cessation regardless of demographics, prior smoking history, or numerous quit attempts,\" stated Dr. Cindy Jacobs PhD, MD, Chief Medical Officer of Achieve. \"With over 34 million smokers in the United States alone and the growin...